FY2025 · ended Dec 31, 2025 · Revenue $106.47M, +350.9% YoY · Filed Mar 9, 2026
Zevra Therapeutics, Inc. (ZVRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $106.5 million and net income of $83.2 million. Free cash flow was -$2.4 million. As of Sep 30, 2026 it held $270.9 million in cash and investments and $63.2 million in total debt.
Revenue (TTM)
$147.76M
+75.1% vs year-ago TTM
Net income (TTM)
$78.02M
+120.8% vs year-ago TTM
Operating cash flow (TTM)
$38.74M
+265.8% vs year-ago TTM
Free cash flow (TTM)
$38.28M
+258.0% vs year-ago TTM
EPS (TTM)
$1.24
Dividend per share
None
Shares outstanding
58.71M
+8.5% vs prior year
Net cash
$207.74M
as of Sep 30, 2026
Operating margin
60.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434647
- Former names
- KEMPHARM, INC (until Feb 24, 2023); KEMPHARM INC (until Jun 30, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M |
| Operating income | -$62.9M | -$87.0M | -$49.6M | -$42.6M | $7.7M |
| Net income | $83.2M | -$105.5M | -$46.0M | -$26.8M | -$8.6M |
| Diluted EPS | $1.35 | — | — | — | -$2.11 |
| Operating cash flow | -$1.6M | -$69.7M | -$33.5M | -$18.7M | $10.4M |
| Free cash flow | -$2.4M | -$69.7M | -$33.8M | -$18.8M | $10.3M |
| Total assets | $284.7M | $178.1M | $172.3M | $115.3M | $132.9M |
| Total liabilities | $130.1M | $138.5M | $110.5M | $40.2M | $5.8M |
| Stockholders' equity | $154.7M | $39.7M | $61.9M | $75.1M | $101.7M |
| Cash and investments | $238.9M | $75.5M | $67.7M | $82.4M | $127.8M |
| Total debt | $63.2M | $60.3M | $999,000 | $1.3M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 869 Zevra Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.